Laropiprant recalled


Merck & Co has said it is recalling Tredaptive cholesterol tablets in response to trial results that raised safety concerns and the recommendations of a European Medicines Agency safety panel.

Tredaptive tablets are approved in the EU and elsewhere – but not in the US – for treating patients with high cholesterol levels. They contain niacin (vitamin B3), which increases levels of ‘good’ HDL cholesterol, and laropiprant, a patent protected compound designed to reduce facial flushing, a common side effect of taking niacin.

The data suggest that the tablets are not as effective as hoped at reducing heart attacks, deaths and strokes in patients with high levels of ‘bad’, LDL cholesterol. They also suggest that the side effects are worse than expected.

Merck & Co said that doctors should stop prescribing the drug and review treatment plans for patients already taking it.

US regulators rejected laropiprant for market approval in 2008.


Related Content

HDL drug class struggling after latest flop

27 May 2012 Business

news image

The failure of another 'good' cholesterol-raising drug and a new genetic study casts shadow over HDL hypothesis

Regulator rebuffs Merck's cholesterol drug

28 May 2008 News Archive

news image

The US Food and Drug Administration (FDA) has unexpectedly refused to approve Merck's cholesterol-lowering drug Cordaptive

Most Read

Refining Avogadro’s number on way to new kilo

21 July 2015 Research

news image

Most precise value yet reduces uncertainty down to 20 atoms in a billion

Weaving is believing

23 July 2015 The Crucible

news image

Philip Ball unpicks the history of science’s woollen wardrobe

Most Commented

Weaving is believing

23 July 2015 The Crucible

news image

Philip Ball unpicks the history of science’s woollen wardrobe

Despair and anger among Greek scientists at universities' finances

17 July 2015 News and Analysis

news image

Little hope that billions of euros in new loans from the EU will improve the situation